However, a recent Cochrane review confirmed that evidence on the efficacy of PSA testing as a prostate cancer screening tool is still lacking [5] and mortality data from two large randomised control trials is a number of years away [6,7]. The gene discussed is KLK3; the disease is prostate carcinoma.